Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan.
Miyauchi Medical Center, JR Takatsuki station NK building 2F, 1-1-1 Akutagawa-cho, Takatsuki-shi, Osaka, 569-1123, Japan.
Arch Osteoporos. 2018 Mar 22;13(1):34. doi: 10.1007/s11657-018-0443-7.
Osteoporosis (OP) causes reduced bone strength and increases risk of fractures. Medical records from specialist clinics in Japan of postmenopausal women with OP and high risk of fracture were analysed. Majority of patients were treated for OP as recommended and were prescribed OP medications soon after high-risk OP diagnosis.
The incidence of osteoporosis (OP) in Japan is predicted to increase significantly in coming decades. Resultant osteoporotic fractures are a significant contributor of economic and social burden among elderly osteoporosis patients. This retrospective chart review was conducted as a response to the current evidence gap in the treatment patterns for OP patients with high risk of fracture in Japan.
This was a multi-centre retrospective chart review that analysed data extracted from the medical records of postmenopausal OP patients at high risk for fracture who received care at 11 specialist clinics and medical centers in Japan for at least 18 to 24 months. Main outcome was OP treatment patterns.
The study included 709 eligible patients of whom 623 (87.9%) were prescribed OP medication during the study period. The most common reason for not taking OP medication was patient unwillingness to take medication. The most common OP medications prescribed initially were minodronic acid (20.1%), alendronate (19.9%), raloxifene (14.1%), weekly teriparatide acetate (12.4%) and eldecalcitol (11.4%). Majority of patients (62.1%) were still taking their initial medication at the end of the 18-24 month follow-up.
A high percentage of patients (87.9%) in Japan received OP medications soon after their high-risk diagnosis, with bisphosphonates, selective estrogen receptor modulators and teriparatide being the predominant treatment options.
骨质疏松症（OP）会导致骨强度降低，增加骨折风险。分析了日本专门诊所中绝经后患有 OP 和高骨折风险的女性的医学记录。大多数患者按照建议接受 OP 治疗，并在高危 OP 诊断后不久即开具 OP 药物。
预计未来几十年日本的骨质疏松症（OP）发病率将显著增加。由此产生的骨质疏松性骨折是老年骨质疏松症患者经济和社会负担的重要因素。由于目前日本高风险骨折的 OP 患者的治疗模式存在证据差距，因此进行了这项回顾性图表审查。
这是一项多中心回顾性图表审查，分析了从日本 11 家专门诊所和医疗中心接受至少 18 至 24 个月治疗的绝经后 OP 高危骨折患者的病历中提取的数据。主要结果是 OP 治疗模式。
该研究纳入了 709 名符合条件的患者，其中 623 名（87.9%）在研究期间接受了 OP 药物治疗。不服用 OP 药物的最常见原因是患者不愿意服用药物。最初开的最常见的 OP 药物是米诺膦酸（20.1%）、阿仑膦酸钠（19.9%）、雷洛昔芬（14.1%）、每周特立帕肽醋酸盐（12.4%）和依骨化醇（11.4%）。大多数患者（62.1%）在 18-24 个月随访结束时仍在服用最初的药物。
日本有很高比例的患者（87.9%）在高危诊断后不久就接受了 OP 药物治疗，双膦酸盐、选择性雌激素受体调节剂和特立帕肽是主要的治疗选择。
